title: [Effect of the anti-inflammatory peptide preparation ingramon on the blood levels of acute-phase proteins and chemokines in patients after coronary stenting].
abstract: OBJECTIVE
  To study the effect of the anti-inflammatory peptide preparation ingramon on the peripheral blood levels of inflammatory markers in patients with exercise-induced stable angina after coronary stenting (CS).
  
  
  METHODS
  The investigation enrolled 64 patients with stable angina who had undergone coronary bypass surgery, of them 34 patients received ingramon in addition to standard therapy. The blood levels of high-sensitive C-reactive protein (hs-CRP), fibrinogen, the chemokines MCP-1, IL-8, IP-10, and MID were measured before and 1, 2, and 7 days and 1, 3, and 6 months after surgery. Twenty patients who had gone coronarography (CG) only were examined as a control group.
  
  
  RESULTS
  In the post CS patients receiving only standard therapy, the levels of hs-CRP and fibrinogen were much higher on days 1, 2, and 7 after surgery than in the CG patients. On day 1 following CS, the increment in hs-CRP correlated with the length of implanted stents. During ingramon therapy, the content of hs-CRP and fibrinogen was considerably lower on days 1, 2, and 7 after CS than in the control group; this trend persisted a month after surgery; there was also a reduction in MCP-1 levels within the first 24 hours after initiation of therapy. The levels of the chemokines IP-10, MIG, and IL-8 were significantly unchanged. CONCLUSION. When added to standard therapy, ingramon exerts a positive effect against risk factors for coronary heart disease (CHD) and its events. Further investigations are required to define the impact of ingramon therapy on prognosis in patients with CHD.
authors.forename: A V
authors.initials: AV
authors.lastname: Potekhina
authors.forename: S I
authors.initials: SI
authors.lastname: Provatorov
authors.forename: T I
authors.initials: TI
authors.lastname: Aref'eva
authors.forename: N B
authors.initials: NB
authors.lastname: Kukhtina
authors.forename: V P
authors.initials: VP
authors.lastname: Masenko
authors.forename: E I
authors.initials: EI
authors.lastname: Kaznacheeva
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Ruleva
authors.forename: E A
authors.initials: EA
authors.lastname: Noeva
authors.forename: M K
authors.initials: MK
authors.lastname: Osiaeva
authors.forename: M V
authors.initials: MV
authors.lastname: Sidorova
authors.forename: Zh D
authors.initials: ZhD
authors.lastname: Bespalova
authors.forename: T L
authors.initials: TL
authors.lastname: Krasnikova
mesh_terms: D000209:Acute-Phase Proteins / Q000032:analysis*; D015906:Angioplasty, Balloon, Coronary; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D018925:Chemokines / Q000097:blood*; D023903:Coronary Restenosis / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood / Q000601:surgery*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000209:Acute-Phase Proteins; D000894:Anti-Inflammatory Agents, Non-Steroidal; D018925:Chemokines; D010446:Peptide Fragments; C542772:ingramon